New
Update on Vitiligo Drug Development in 2023
Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo.
Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo is a much neglected disease and specific treatments for the disease are not available. AB1001 is a novel class of compounds, discovered and developed at Ahammune, that has the potential to not only limit the progression of the disease but also reverses the pigmentation loss. The successful completion of Phase 1 of the molecule brings a much wanted treatment closer to the patients. We are looking forward to the compound becoming a drug shortly.”
Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research had partnered for the first in human studies with Ahammune’s investigational new drug AB1001.
FAQOther Questions
- Red Wine and Vitiligo
Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...
- What are rules for military service entry with vitiligo?
Military service · Patient guide How do military-service rules for vitiligo differ across countries? There is no global standard. Every country writes its own entry rules, and m...
- Any link between vitiligo and military service?
While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.